Form 4 for NBIX NEUROCRINE BIOSCIENCES INC

Accepted 2026-09-15 17:05:05 ET · period of report 2026-09-11 · accession 0001567160-26-000009 · SEC index · Original document

Summary rows

Aggregated the way they appear in lists: one row per insider, transaction code and security table.

X	Filed	Traded	Ticker	Insider	Title	Type	Price	Qty	Owned	ΔOwn	Value
M	2026-09-15 17:05	2026-09-11	NBIX	Gano Kyle	CEO, Dir	A - Grant	$0.00	+8,117	155.7K	+5%	$0
M	2026-09-15 17:05	2026-09-11	NBIX	Gano Kyle	CEO, Dir	F - Tax	$156.22	-4,380	154.7K	-3%	-$684.2K

Purchase Sale Sale after option exercise All abbreviations

#	Table	Security	Date	Code	A/D	Shares	Price	Owned after	Own	Exercise / expiry	Underlying	Footnotes
1	Common	Common Stock	2026-09-11	A	A	6,275	$0.00	157,266	D	—	—	(F1) The Reporting Person was previously granted performance restricted stock units (PRSUs) that vest upon the achievement of certain performance metrics, the achievement of one of which was certified on September 11, 2026. (F2) Includes an aggregate of 176 shares purchased on February 27, 2026 from the Neurocrine Biosciences, Inc. 2018 Employee Stock Purchase Plan.
2	Common	Common Stock	2026-09-11	F	D	3,386	$156.22	153,880	D	—	—	(F3) Shares withheld by Neurocrine Biosciences, Inc. (the "Company" or "Issuer") to satisfy tax withholding requirements on vesting of PRSUs. No shares were sold.
3	Common	Common Stock	2026-09-11	A	A	1,842	$0.00	155,722	D	—	—	(F1) The Reporting Person was previously granted performance restricted stock units (PRSUs) that vest upon the achievement of certain performance metrics, the achievement of one of which was certified on September 11, 2026.
4	Common	Common Stock	2026-09-11	F	D	994	$156.22	154,728	D	—	—	(F3) Shares withheld by Neurocrine Biosciences, Inc. (the "Company" or "Issuer") to satisfy tax withholding requirements on vesting of PRSUs. No shares were sold.